Intrepid Alliance Inc Co Browne Consulting Group

Nonprofit profile at a glance

EIN
352711268
IRS 990 coverage
2021–2024
Forms available
Form 990 2024
Location
Cambridge, MA, USA
Phone
7817572081
Rating confidence
Limited
Sector
Professional Societies, Associations

Reported finances

Revenue
$2,245,192
Expenses
$1,930,908
Assets
$2,256,819
Liabilities
$126,649

Source: IRS Form 990. Selected filing: tax year 2024. Amounts in USD.

Leadership & pay

11 people listed

Executive titles in this filing

  • JAMES ANDERSON (PRESIDENT)

Highest reported compensation

  • NINA HILL (SECRETARIAT): $298,844 total reported compensation

Source: IRS Form 990. Selected filing: tax year 2024. Names and roles reflect this filing, not necessarily current officeholders.

Overview

Mission

The primary purpose of the corporation is to promote the common business interest of its members of advancing global health security through pandemic preparedness efforts. The corporation will pursue this purpose by promoting the development of new treatments for emerging viral pandemic pathogens through coordinated early science, policy and advocacy, stakeholder engagement that facilitates information sharing, and advancing and creating efficiencies in early research and development among its members and others in the antiviral r&d ecosystem. In this way the corporation aims to support the 100 day mission, an international effort by the international pandemic preparedness secretariat (ipps.org) "to prepare as much as possible so that within the first 100 days a pandemic threat is identified an initial regimen of therapeutics" can be made available by research enterprises that are safe, effective and affordable.

What it reported doing in 2024

Beyond covid-19, globalization, urban expansion, and exploitation of natural habitats suggest humanity will face new forms of respiratory and other pathogens that hold the potential to cause pandemics. Orally available small-molecule antiviral drugs for rapid mobilization and distribution are a critical tool to protect societies from another viral pandemic. Unlike some vaccines and antibodies, antiviral therapies might be less prone to the impact of virus genetic evolution, may be effective against a broad range of viruses, and can change the course of disease even after infection. Most small molecule antivirals can be produced rapidly and cost-effectively at a global scale in existing facilities, but they require years to discover and develop, so it is critical to promote and support research, advocacy, and scientific information sharing across the academic biotech and pharmaceutical industry. In order to create efficiencies in the r&d ecosystem, the corporation will collaborate with partners in other sectors and its members in exploring redundancies and opportunities to collaborate for the benefit of humanity such as sharing new research findings, creating guidelines such as target product profiles, benchmarking global r&d efforts against pathogens of pandemic concern and creating a listing of promising lead product candidates by researchers globally. We hope to accelerate the collective understanding of viral targets and increase the likelihood of the r&d ecosystem in identifying promising leads. The corporation intends to facilitate further scientific information sharing by developing white papers on relevant topics, performing a landscape and needs assessment across public and private antiviral research sectors, and providing knowledge-sharing opportunities through organizing meetings and seminars. The corporation also organized and produced a global summit on antiviral preparedness for 100 stakeholders, published and disseminated the antiviral summit proceedings and recommendations, researched, analyzed and authored the antiviral clinical development landscape for publication in january 2024 and developed a target compound profile to guide academic, biotech, pharma and government drug developers in their r&d for antivirals.

Operating model

Revenue model
Other-operating. 100% of the money available for current operations came from other operating revenue.
Distribution model
Cannot be determined from the filing. The filing does not provide enough consistent spending detail to tell whether the nonprofit works directly or through others.

The verdict

- The available evidence is not sufficient to produce an overall rating for this filing. This is not a warning sign.

Rating breakdown

  • Financial Efficiency: NotEnoughData
  • Transparency & Controls: 52
  • Accountability: 74
  • Sustainability: 55
  • Growth: 60

Detailed rating inputs

Financial Efficiency

  • Mission deployment rate: Limited
  • Program expense ratio: Limited
  • Fundraising efficiency: Limited

Transparency & Controls

  • Consistency checks: 100%; rating input score 100; 63rd percentile among comparable filings
  • Pay-setting controls: 3 of 6 controls in place; rating input score 50
    • Compensation committee: Missing
    • Independent consultant: Missing
    • Other Form 990s reviewed: Pass
    • Written employment contract: Pass
    • Compensation survey or study: Missing
    • Board or committee approval: Pass
  • Foreign activity oversight: Scored; rating input score 0
  • Grant itemization coverage: Scored; rating input score 0
  • Major donor itemization: Limited
  • Related-party transparency: Limited

Accountability

  • Independent voting board: 100%; rating input score 100; 63rd percentile among comparable filings
  • Governance controls: 3 of 8 controls in place; rating input score 38
    • Conflict-of-interest policy: Pass
    • Whistleblower policy: Fail
    • Document-retention policy: Fail
    • CEO compensation review process: NotApplicable
    • Other executive compensation review process: Fail
    • Form 990 shared with the board: Pass
    • Board meeting minutes documented: Pass
    • Audit committee oversight: Missing
    • Independent financial-statement audit: Fail

Sustainability

  • Operating margin: 14%; rating input score 69; 69th percentile among comparable filings
  • Total-asset coverage ratio: 1.17; rating input score 42; 42nd percentile among comparable filings
  • Liabilities to assets ratio: 0.06; rating input score 68; 68th percentile among comparable filings
  • Officer compensation ratio: 15.5%; rating input score 18; 18th percentile among comparable filings

Growth

  • Program expense growth: Limited
  • Revenue growth: 36.5% per year; rating input score 100; 96th percentile among comparable filings
  • Asset growth: 35% per year; rating input score 100; 95th percentile among comparable filings

Details

  • Where the money goes: Financial trends and filed revenue, expense, asset, and liability detail
  • Governance: 8 of 8 board members independent · 3 of 8 filing controls reported
  • Programs: 1 filed program accomplishment
  • Leadership: top reported pay $299K · 11 people listed · 3 of 6 pay-setting controls reported
  • Highest-paid contractors: 5 contractors listed · $1.1M reported
  • Consistency: 8 of 8 current checks pass
  • Schedules: 4 filed schedules · includes foreign activity and executive pay
  • Filing history: 4 filing years from 2021 to 2024
  • Contacts: How to reach this organization
  • Money network: 1 filed money-flow record
  • Grant readiness: Federal tax and exclusion status, award history, and grant-maker relationships.
  • People: Everyone the filings name, and which of them the filings identify by more than a name.

Key Signals

Signals prioritize questions for review. They are not findings of misconduct.

  • High — Transparency & Controls: Foreign activity oversight scored 0/100.
  • High — Transparency & Controls: Grant itemization coverage scored 0/100.
  • Moderate — Accountability: Governance controls: 4 of 7 not reported.
  • Moderate — Sustainability: Total-asset coverage ratio scored 42/100.
  • High — Sustainability: Officer compensation ratio scored 18/100.